Login to Your Account



Healthiosxchange to Capitalize on New Crowdfunding Flexibility

By Marie Powers
Staff Writer

Monday, August 5, 2013

Despite a flood of capital into biotech initial public offerings and breathtaking market runs, venture capital (VC) is still shunning many early stage life science companies. According to a May MoneyTree report by PwC and the National Venture Capital Association, VC investment in biotechnology and medical device firms dropped in value and volume during the first quarter of 2013 as investors turned to less capital-intensive industries.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription